<?xml version="1.0" encoding="utf-8"?>
<File id="100">
  <Title><![CDATA[<p>What is the study evaluating a delayed fractional dose of RTS,S?</p>]]></Title>
  <HtmlTextKey><![CDATA[]]></HtmlTextKey>
  <HtmlText><![CDATA[<p>This proof-of concept study (Malaria-071)<sup>(a) </sup>aims to evaluate an increased capacity of RTS,S/AS01 to protect na&iuml;ve adults against a sporozoite challenge when administered as an alternative dose/schedule (third dose is a 1/5<sup>th</sup> of the standard dose and given at month 7) as compared to the standard dose and schedule (months 0, 1 and 2). A previous study<sup>(b)</sup> had previously indicated a potential for this concept using RTS,S with another adjuvant system, AS02. Results are expected in 2014.</p>]]></HtmlText>
  <Topic>OTHER MALARIA VACCINES</Topic>
  <SubTopic>GSK SECOND GENERATION MALARIA VACCINES</SubTopic>
  <References><![CDATA[<ol style="list-style-type:lower-alpha">
	<li><em>ClinicalTrials.gov - NCT01857869</em></li>
	<li><em>Stoute J. et al. NEJM 1997; 336: 86-9</em></li>
</ol>]]></References>
  <pdf>xml/content/100/100.pdf</pdf>
  <docx>xml/content/100/100.docx</docx>
  <contentLastUpdated>2014-03-03</contentLastUpdated>
  <RelatedFiles />
</File>